Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05864885
Other study ID # ANR C002
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date June 9, 2023
Est. completion date July 17, 2023

Study information

Verified date May 2023
Source Aneira Pharma, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be a single center, open-label study of a single concentration of ANR- 001.1. The solution will be applied to the scalp of 14 male subjects by study staff once daily for 7 days.


Description:

At screening, subjects will sign informed consent and inclusion and exclusion will be reviewed for each subject. Screening data will include demographics, medical history, concomitant medications, physical examination, weight, O2 sat, vital signs laboratory evaluation (CMP, CBC, UA), and ECG. At Day 1, a physical exam, weight, O2 sat, vital signs (including BP, pulse, respiratory rate and temperature) and review of concomitant medications will be performed, and admission criteria reviewed. If criteria are met, the study staff will administer the first dose of study medication to the area of hair loss on the scalp (8 cm x 6 cm). If there is no hair loss the dose will be administered to the crown of the head (8 cm x 6 cm). The study staff will continue to administer the study medication to the same area of the scalp of the subject, once daily for Study Days 1, 2, 3, 4, 5, 6, and 7. Daily subject visits will include vital signs, review of adverse events and concomitant medications. PK draws and ECGs will take place at Study Days 1, 2, 7 and 8, following the first dose and the last doses, respectively.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 14
Est. completion date July 17, 2023
Est. primary completion date July 17, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: Males between age 18 to 65 years, in general good health. Good health is defined as a subject without any active diseases. Not included in active diseases are: - Migraines - Non-hospitalized depression o Asthma - Cholecystectomy - Gilbert's syndrome - Clinical diagnosis of AGA with grade II to VI hair loss on Norwood Hamilton Classification System - Subjects of any Fitzpatrick skin type or race provided their degree of skin pigmentation does not, in the Investigator's opinion, interfere with study assessments. - No known allergy to ANR-001.1 or any of its components. - Subject is willing to avoid extensive sun exposure, phototherapy, or use of tanning salon for the duration of the study. Exclusion Criteria: If subjects have a BMI outside of the range of 18-35kg/m2 - Subjects using a minoxidil product (e.g., Rogaine or generic Rogaine) or a latanoprost product (e.g., Xalatan or generic Xalatan) within 30 days of the start of Day 1 of the study. - Subjects whose vital signs, ECG, safety labs or physical exam results are clinically significant in the opinion of the investigator. - Subjects have a skin condition that, in the Investigators opinion, could interfere with study assessment or put the subject at undue risk by study participation. - Subjects with an active or recent (within 30 days before Day 1) disease or infection, or chronic dermatological condition (eczema, psoriasis, infection, etc.). - Subjects with known or suspected hypersensitivity or allergic reaction to any of the active or inactive components of the test treatment. - Current enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Minoxidil
Topical formulation applied once a day.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Aneira Pharma, Inc. DataPharm Australia, CMAX Clinical Research, Agilex Australia

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetic data: Cmax Individual and mean maximum plasma concentration (Cmax) 7 days
Primary Pharmacokinetic data: tmax Individual and mean tmax 7 days
Primary Pharmacokinetic data: Half-life (t1/2) Individual and mean half-life (t1/2) 7 days
Primary Pharmacokinetic data: AUC Individual and mean area under the concentration-time curve calculated from time zero to the last observable concentration at time t (AUC0-t) 7 days
Primary Pharmacokinetic data: Drug clearance Individual and mean apparent clearance of drug from plasma 7 days
Primary Safety : Skin TEAEs Incidence of treatment-emergent adverse events related to skin irritation at the administration site 7 days
Primary Safety: Systemic TEAEs Incident of systemic treatment-emergent adverse events 7 days
Primary Safety: Evaluation of QTs Interval Prolongation Change from baseline in the frequency of marked QTc prolongation at each visit where ECG is performed 7 days
See also
  Status Clinical Trial Phase
Completed NCT02591355 - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment N/A
Withdrawn NCT03852992 - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Phase 2
Recruiting NCT06239207 - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia Phase 2
Completed NCT04945226 - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Phase 1/Phase 2
Completed NCT01548066 - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss Phase 2
Completed NCT01437163 - Treatment of Androgenetic Alopecia in Males and Females N/A
Completed NCT01226459 - Clinical Trial in Females for Female Pattern Hair Loss Phase 3
Recruiting NCT06118866 - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia Phase 2
Completed NCT06149221 - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss N/A
Withdrawn NCT04882969 - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia N/A
Completed NCT01231607 - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Phase 3
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT02729415 - Point-of-Care Adipose-derived Cells for Hair Growth N/A
Completed NCT02279823 - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Phase 2
Not yet recruiting NCT01227031 - Pharmacogenomic Study of Androgenetic Alopecia N/A
Completed NCT00981461 - Treatment of Androgenetic Alopecia in Females, 9 Beam N/A
Completed NCT01451021 - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss Phase 2
Completed NCT00151515 - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Phase 3
Completed NCT03694067 - Androgenetic Alopecia and the JAK-STAT Pathway
Completed NCT03689452 - The Effect of Platelet Rich Plasma on Non-scarring Alopecia N/A